CRISPR/Cas9 工程化 HLA 缺失肾小球内皮细胞用于预测肾移植受者致病性非 HLA 抗体
研究利用 CRISPR/Cas9 敲除 B2M 和 CIITA 基因获得 HLA I 类和 II 类缺陷的肾小球内皮细胞(CiGEnCΔHLA),建立非 HLA 抗体检测免疫分析(NHADIA),检测 389 例连续肾移植受者移植前血清,并与 951 份 adequate 活检标本的移植后组织学关联。结果显示移植前 NHADIA 信号与肾小球炎、微血管炎症和 ABMRh 正相关,阈值 1.87 可强区分 ABMRh 高风险受者,NHADIA 状态与 HLA-DSA 是 ABMRh 的独立且协同预测因子。
要点
- CiGEnCΔHLA 细胞形态和表型与亲本细胞系无法区分。
- 既往移植史是移植前 NHADIA 结果的主要决定因素(P<0.001)。
- 移植前 NHADIA 阈值 1.87 强区分 ABMRh 最高风险受者(P=0.005,log-rank 检验)。
核心结论
- NHADIA 可识别非 HLA 抗体,并独立于 HLA-DSA 强预测移植物内皮损伤。
研究设计与样本
- 利用 CRISPR/Cas9 诱导 B2M 和 CIITA 基因破坏,获得 HLA I 类和 II 类缺陷的肾小球内皮细胞(CiGEnCΔHLA),建立非 HLA 抗体检测免疫分析(NHADIA)。
- 用流式细胞术评估 389 例连续肾移植受者移植前血清对非 HLA 抗原的反应性。
- 将 NHADIA 信号强度与 951 份 adequate 活检标本评估的移植后移植物组织学关联。
主要发现
- CiGEnCΔHLA 细胞在形态和表型上与亲本细胞系 CiGEnC 无法区分。
- 既往移植史是移植前 NHADIA 结果的主要决定因素(P<0.001)。
- 按移植前 NHADIA 三分位数分层 3 个月同种异体移植物活检标本(n=298),较高非 HLA 抗体水平与肾小球炎增加正相关(P=0.002)、与微血管炎症增加正相关(P=0.003)、与 ABMRh 增加正相关(P=0.03)。
- 移植前 NHADIA 阈值 1.87 强区分 ABMRh 最高风险的肾移植受者(P=0.005,log-rank 检验)。
- 多因素 Cox 模型证实 NHADIA 状态和 HLA-DSA 是 ABMRh 的独立但协同预测因子。
关键数值与推荐
- 移植前 NHADIA 三分位数分层与 3 个月活检标本的肾小球炎(P=0.002)、微血管炎症(P=0.003)和 ABMRh(P=0.03)正相关。
- 移植前 NHADIA 阈值 1.87 区分 ABMRh 最高风险受者(P=0.005,log-rank 检验)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After kidney transplantation, donor-specific antibodies against human leukocyte antigen donor-specific antibodies (HLA-DSAs) drive antibody-mediated rejection (ABMR) and are associated with poor transplant outcomes. However, ABMR histology (ABMRh) is increasingly reported in kidney transplant recipients (KTRs) without HLA-DSAs, highlighting the emerging role of non-HLA antibodies (Abs). METHODS: W e designed a non-HLA Ab detection immunoassay (NHADIA) using HLA class I and II-deficient glomerular endothelial cells (CiGEnCΔHLA) that had been previously generated through CRISPR/Cas9-induced B2M and CIITA gene disruption. Flow cytometry assessed the reactivity to non-HLA antigens of pretransplantation serum samples from 389 consecutive KTRs. The intensity of the signal observed with the NHADIA was associated with post-transplant graft histology assessed in 951 adequate biopsy specimens. RESULTS: W e sequentially applied CRISPR/Cas9 to delete the B2M and CIITA genes to obtain a CiGEnCΔHLA clone. CiGEnCΔHLA cells remained indistinguishable from the parental cell line, CiGEnC, in terms of morphology and phenotype. Previous transplantation was the main determinant of the pretransplantation NHADIA result (P<0.001). Stratification of 3-month allograft biopsy specimens (n=298) according to pretransplantation NHADIA tertiles demonstrated that higher levels of non-HLA Abs positively correlated with increased glomerulitis (P=0.002), microvascular inflammation (P=0.003), and ABMRh (P=0.03). A pretransplantation NHADIA threshold of 1.87 strongly discriminated the KTRs with the highest risk of ABMRh (P=0.005, log-rank test). A multivariate Cox model confirmed that NHADIA status and HLA-DSAs were independent, yet synergistic, predictors of ABMRh. CONCLUSION: The NHADIA identifies non-HLA Abs and strongly predicts graft endothelial injury independent of HLA-DSAs.
引用
- Lamarthée B, Burger C, Leclaire C, et al. CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. J Am Soc Nephrol. 2021. PMID: 35167486. doi:10.1681/ASN.2021050689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。